The Indian Patent Office has reportedly rejected an application covering US company Abraxis BioScience’s cancer drug Abraxane.
Novartis has sued Apotex at the US District Court for the District of New Jersey to protect its drug Zometa from generic competition.
A US appeals court has ruled that Actavis’s attempt to force Alzheimer’s patients to switch from one medication to another before generic companies entered the market was anti-competitive.
Israel-based pharmaceutical company Teva will have to fork out $1.2 billion after a long-running dispute with the US Federal Trade Commission over a controversial ‘pay-for-delay’ case was settled.
A US appeals court has issued a mixed judgment in a patent dispute that saw Novartis file infringement claims against both Watson Pharmaceuticals and Par Pharmaceutical.
The Supreme Court of India has ordered Glenmark Pharmaceuticals to stop making generic versions of Merck Sharp & Dohme’s diabetes drugs Januvia and Janumet.
The Foundation for AIDS Research has warned that the Trans-Pacific Partnership’s changes to IP policy could restrict access to affordable generic medicines in low and middle income countries.
The Supreme Court of California has ruled that so-called “pay-for-delay” patent settlements can be challenged under state antitrust law in a case centering on Bayer’s antibiotic drug Cipro.
A US court has ruled on how five claims in two patents related to acne drug Absorica should be construed, in a patent infringement case between Canada-based Cipher Pharmaceuticals and Actavis.
Drug maker Shire, alongside two other companies, has sued Amneal Pharmaceuticals for allegedly infringing a patent related to Lialda, a drug for treating ulcerative colitis.